178 related articles for article (PubMed ID: 18097299)
1. Nonalcoholic fatty liver disease induced by leuprorelin acetate.
Gabbi C; Carubbi F; Losi L; Loria P; Costantini M; Bertolotti M; Carulli N
J Clin Gastroenterol; 2008 Jan; 42(1):107-10. PubMed ID: 18097299
[TBL] [Abstract][Full Text] [Related]
2. Leuprorelin acetate granulomas: case reports and review of the literature.
Yasukawa K; Sawamura D; Sugawara H; Kato N
Br J Dermatol; 2005 May; 152(5):1045-7. PubMed ID: 15888168
[TBL] [Abstract][Full Text] [Related]
3. Granulomas induced by subcutaneous injection of leuprorelin acetate.
Sakamoto R; Higashi Y; Mera K; Kanekura T; Kanzaki T
J Dermatol; 2006 Jan; 33(1):43-5. PubMed ID: 16469084
[TBL] [Abstract][Full Text] [Related]
4. Life-threatening anaphylaxis to leuprorelin acetate depot: case report and review of the literature.
Fujisaki A; Kondo Y; Goto K; Morita T
Int J Urol; 2012 Jan; 19(1):81-4. PubMed ID: 22050405
[TBL] [Abstract][Full Text] [Related]
5. [Cutaneous epithelioid granulomas caused by subcutaneous infusion of leuprorelin acetate: a case report].
Tachibana M; Yamano Z; Kusuda Y; Hara S; Shimogaki H; Hamami G
Hinyokika Kiyo; 2004 Mar; 50(3):199-202. PubMed ID: 15148774
[TBL] [Abstract][Full Text] [Related]
6. Injection-site granulomas due to the administration of leuprorelin acetate for the treatment of prostatic cancer.
Shiota M; Tokuda N; Kanou T; Yamasaki H
Fukuoka Igaku Zasshi; 2007 Jul; 98(7):301-4. PubMed ID: 17710895
[TBL] [Abstract][Full Text] [Related]
7. Leuprorelin acetate in prostate cancer: a European update.
Persad R
Int J Clin Pract; 2002 Jun; 56(5):389-96. PubMed ID: 12137449
[TBL] [Abstract][Full Text] [Related]
8. Randomised crossover trial to assess the tolerability of LHRH analogue administration.
Williams G; Lindsay S; Bowsher WG
Prostate Cancer Prostatic Dis; 2003; 6(2):187-9. PubMed ID: 12806381
[TBL] [Abstract][Full Text] [Related]
9. [Surgical management of inflammatory granuloma which developed following subcutaneous injection of leuprorelin acetate: a case report].
Oida T; Shichiri Y; Takao N; Kanno T; Kanamaru H
Hinyokika Kiyo; 2005 Jul; 51(7):487-9. PubMed ID: 16119817
[TBL] [Abstract][Full Text] [Related]
10. Noninfective cutaneous granuloma with leuprorelin acetate--reality or myth.
Dangle P; Palit V; Sundaram SK; Weston P
Urology; 2007 Apr; 69(4):779.e5-6. PubMed ID: 17445679
[TBL] [Abstract][Full Text] [Related]
11. Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report.
Chang JI; Bucci J
J Med Case Rep; 2016 Nov; 10(1):323. PubMed ID: 27836000
[TBL] [Abstract][Full Text] [Related]
12. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.
Montgomery BS; Borwell JP; Higgins DM
Prostate Cancer Prostatic Dis; 2005; 8(1):66-8. PubMed ID: 15700050
[TBL] [Abstract][Full Text] [Related]
13. [Investigation of incidence and risk factors of subcutaneous granulomas induced by injection of leuprorelin acetate].
Fukui S; Nakai Y; Matsumoto Y; Kagebayashi Y; Samma S
Hinyokika Kiyo; 2015 Feb; 61(2):55-9. PubMed ID: 25812594
[TBL] [Abstract][Full Text] [Related]
14. Granuloma caused by subcutaneous injection of leuprorelin acetate product: case report and histopathological findings.
Ouchi T; Koyama T; Miyata N; Sugiura M
J Dermatol; 2006 Oct; 33(10):719-21. PubMed ID: 17040504
[TBL] [Abstract][Full Text] [Related]
15. A morphological study of granulomas induced by subcutaneous injection of leuprorelin acetate.
Watanabe T; Yamada N; Yoshida Y; Yamamoto O
J Cutan Pathol; 2009 Dec; 36(12):1299-302. PubMed ID: 19469875
[TBL] [Abstract][Full Text] [Related]
16. Leuprolide acetate given by a subcutaneous extended-release injection: less of a pain?
Cox MC; Scripture CD; Figg WD
Expert Rev Anticancer Ther; 2005 Aug; 5(4):605-11. PubMed ID: 16111462
[TBL] [Abstract][Full Text] [Related]
17. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
[TBL] [Abstract][Full Text] [Related]
18. Effects of combination therapy with a luteinizing hormone-releasing hormone agonist and chlormadinone acetate on rat prostate weight and plasma testosterone levels.
Gotanda K; Shinbo A; Okada M; Nakano Y; Kobayashi H; Sasaki T; Hagiwara M; Akaza H
Prostate Cancer Prostatic Dis; 2003; 6(1):66-72. PubMed ID: 12664069
[TBL] [Abstract][Full Text] [Related]
19. Successful recovery from interstitial pneumonitis, induced by bicalutamide and leuprorelin acetate given as treatment for prostate cancer.
Shioi K; Sakai N; Yoshida M; Nakamura M
Hinyokika Kiyo; 2005 Mar; 51(3):211-4. PubMed ID: 15852680
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]